StockData
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. (XENE) stock

XENENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$38.78−0.48 (-1.22%)

Close on Nov 17, 2026Market cap $3.76BP/E –Yield –

Xenon Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Xenon Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$337.52M. For fiscal 2025 it was -$279.12M. The highest annual figure on record is $45.57M in fiscal 2012.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$279.12M–
FY2024Dec 31, 2024-$181.39M–
FY2023Dec 31, 2023-$151.11M–
FY2022Dec 31, 2022-$101.03M–
FY2021Dec 31, 2021-$69.50M–
FY2020Dec 31, 2020-$48.12M–
FY2019Dec 31, 2019-$4.71M–
FY2018Dec 31, 2018-$34.72M–
FY2017Dec 31, 2017-$28.73M–
FY2016Dec 31, 2016-$19.57M–
FY2015Dec 31, 2015-$18.10M-6905.6%
FY2014Dec 31, 2014$266.00K–
FY2013Dec 31, 2013-$3.32M-107.3%
FY2012Dec 31, 2012$45.57M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$95.39M–
Q1 FY2026Mar 31, 2026-$88.90M–
Q4 FY2025Dec 31, 2025-$81.48M–
Q3 FY2025Sep 30, 2025-$71.75M–
Q2 FY2025Jun 30, 2025-$64.23M–
Q1 FY2025Mar 31, 2025-$61.65M–
Q4 FY2024Dec 31, 2024-$54.39M–
Q3 FY2024Sep 30, 2024-$49.67M–
Q2 FY2024Jun 30, 2024-$31.15M–
Q1 FY2024Mar 31, 2024-$46.19M–
Q4 FY2023Dec 31, 2023-$35.40M–
Q3 FY2023Sep 30, 2023-$48.08M–
Q2 FY2023Jun 30, 2023-$33.22M–
Q1 FY2023Mar 31, 2023-$34.41M–
Q4 FY2022Dec 31, 2022-$35.33M–
Q3 FY2022Sep 30, 2022-$30.40M–
Q2 FY2022Jun 30, 2022-$16.87M–
Q1 FY2022Mar 31, 2022-$18.43M–
Q4 FY2021Dec 31, 2021-$20.71M–
Q3 FY2021Sep 30, 2021-$15.01M–
Q2 FY2021Jun 30, 2021-$13.08M–
Q1 FY2021Mar 31, 2021-$20.71M–
Q4 FY2020Dec 31, 2020-$13.11M-166.3%
Q3 FY2020Sep 30, 2020-$11.15M–
Q2 FY2020Jun 30, 2020-$10.79M–
Q1 FY2020Mar 31, 2020-$13.07M–
Q4 FY2019Dec 31, 2019$19.79M–
Q3 FY2019Sep 30, 2019-$7.06M–
Q2 FY2019Jun 30, 2019-$8.75M–
Q1 FY2019Mar 31, 2019-$8.70M–
Q4 FY2018Dec 31, 2018-$7.24M–
Q3 FY2018Sep 30, 2018-$13.73M–
Q2 FY2018Jun 30, 2018-$5.54M–
Q1 FY2018Mar 31, 2018-$8.22M–
Q4 FY2017Dec 31, 2017-$6.84M–
Q3 FY2017Sep 30, 2017-$8.63M–
Q2 FY2017Jun 30, 2017-$6.80M–
Q1 FY2017Mar 31, 2017-$6.46M–
Q4 FY2016Dec 31, 2016-$4.67M–
Q3 FY2016Sep 30, 2016-$4.52M–

More Xenon Pharmaceuticals figures

See a number that looks wrong?